donafenib

functions as a multikinase inhibitor

Also Known As:

2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-(methyl-d3)-; 4-(4-(((4-Chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)phenoxy)-N-(2H3)methyl-2-pyridinecarboxamide; CM-4307; Zepsun

Networked: 26 relevant articles (7 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - donafenib: 26

Experts

1.	Meng, Rui: 2 articles (10/2022 - 01/2022)
2.	Qiu, Yijin: 2 articles (10/2022 - 01/2022)
3.	Zhou, Ting: 2 articles (10/2022 - 01/2022)
4.	Zhu, Hong: 2 articles (09/2021 - 06/2021)
5.	Bai, Yaowei: 2 articles (01/2021 - 01/2021)
6.	Chen, Yang: 2 articles (01/2021 - 01/2021)
7.	Huang, Songjiang: 2 articles (01/2021 - 01/2021)
8.	Li, Tongqiang: 2 articles (01/2021 - 01/2021)
9.	Liu, Jiacheng: 2 articles (01/2021 - 01/2021)
10.	Shi, Qin: 2 articles (01/2021 - 01/2021)

Related Diseases

1.	Hepatocellular Carcinoma (Hepatoma) 11/01/2019 - "Conclusion: The results from this phase 1b trial indicate a favorable safety profile and notable anticancer efficacy of donafenib for treating advanced hepatocellular carcinoma. " 11/01/2019 - "This phase 1b trial aimed to assess the safety, pharmacokinetics and efficacy of donafenib in treating Chinese patients with advanced hepatocellular carcinoma. " 11/01/2019 - "Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: report from a phase 1b trial." 01/01/2022 - "Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China." 02/01/2023 - "Donafenib in hepatocellular carcinoma."
2.	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/01/2023 - "Safety and efficacy of GEMOX plus donafenib and tislelizumab as first-line therapy for advanced epithelial malignant biliary tract cancer." 01/01/2023 - "This study was aimed to evaluate the safety and the efficacy of gemcitabine and oxaliplatin (GEMOX) combined with donafenib plus tislelizumab as the first-line treatment for patients with unresectable biliary tract cancer (BTC). "
3.	Colorectal Neoplasms (Colorectal Cancer) 09/17/2021 - "This case report provides clinicians with a safe and effective option for donafenib as a later-line treatment option for patients with metastatic colorectal cancer to improve their overall survival and quality of life."
4.	Thyroid Neoplasms (Thyroid Cancer) 01/01/2023 - "The phase II/III study of donafenib was initiated when there was no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). " 01/01/2023 - "Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer." 01/01/2021 - "Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial." 01/01/2021 - "A 61-year-old woman was diagnosed with progressive metastatic radioactive iodine refractory differentiated thyroid cancer and underwent multitargeted tyrosine kinase inhibitor (TKI) Donafenib therapy. "
5.	Neoplasms (Cancer) 01/01/2023 - "A comparison of survival time between the two groups showed that the survival rate and progression-free survival in the Donafenib group were higher than those in the Lunvatinib group (P < 0.05), and the main risk factor affecting the survival rate was the number of multiple tumors. " 01/01/2021 - "To investigate the efficiency and safety of callispheres beads loaded with donafenib (DCBs) for embolization in a VX2 liver tumor, as well as the improvement of tumor angiogenesis following embolization. " 01/01/2021 - "Donafenib-Loaded Callispheres Beads Embolization in a VX2 Liver Tumor: Investigating Efficacy, Safety, and Improvement of Tumor Angiogenesis After Embolization." 01/01/2021 - "To evaluate the effect and immune response of transcatheter arterial embolization (TAE) combined with donafenib in rabbit VX2 liver tumor model. " 01/01/2021 - "Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8+ T-Cell Infiltration in Rabbit VX2 Liver Tumor."

Related Drugs and Biologics

1.	Sorafenib (BAY 43-9006)
2.	tislelizumab
3.	lenvatinib
4.	Oxaliplatin (Eloxatin)
5.	Gemcitabine
6.	Iodine
7.	Deuterium
8.	Angiogenesis Inhibitors
9.	Oxycodone (Oxycontin)
10.	Morphine (MS Contin)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Drug Tapering